CYTOVIR-3 Antiviral Peptide Drug

CYTOVIR-3 activates the mechanisms of innate immunity in cells, as well as regulates inflammatory reactions, protecting the body from excessive inflammation, which is especially common with influenza. According to clinical studies, it has a reliable therapeutic and prophylactic efficacy, which is manifested in a decrease in the incidence of morbidity, a reduction in its duration, as well as in a significant decrease in the frequency of severe and prolonged forms of influenza and ARVI.

According to the study, the antiviral drug CYTOVIR-3 suppresses the multiplication of the SARS-CoV-2 virus, which is the causative agent of the new coronavirus infection COVID-19. The corresponding changes have been made to the instructions for medical use of the drug. In this regard, the CYTOVIR-3 drug can serve as a reliable means of prevention, including emergency prevention (if an infection is suspected), of COVID-19 disease.